Bruce G Haffty1, Linda M McCall2, Karla V Ballman3, Sarah McLaughlin4, Reshma Jagsi5, David W Ollila6, Kelly K Hunt7, Thomas A Buchholz8, Judy C Boughey9. 1. Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. Electronic address: hafftybg@cinj.rutgers.edu. 2. Alliance Statistics and Data Center, Duke University, Durham, North Carolina. 3. Weill Medical College of Cornell University, New York, New York. 4. Mayo Clinic, Jacksonville, Florida. 5. University of Michigan, Ann Arbor, Michigan. 6. University of North Carolina, Chapel Hill, North Carolina. 7. Department of Breast Surgical Oncology, MD Anderson Cancer Center, Houston, Texas. 8. MD Anderson Cancer Center, Houston, Texas. 9. Mayo Clinic, Rochester, Minnesota.
Abstract
PURPOSE: American College of Surgeons Oncology Group Z1071 was a prospective trial evaluating the false negative rate of sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial node-positive disease. Radiation therapy (RT) decisions were made at the discretion of treating physicians, providing an opportunity to evaluate variability in practice patterns following NAC. METHODS AND MATERIALS: Of 756 patients enrolled from July 2009 to June 2011, 685 met all eligibility requirements. Surgical approach, RT, and radiation field design were analyzed based on presenting clinical and pathologic factors. RESULTS: Of 401 node-positive patients, mastectomy was performed in 148 (36.9%), mastectomy with immediate reconstruction in 107 (26.7%), and breast-conserving surgery (BCS) in 146 patients (36.4%). Of the 284 pathologically node-negative patients, mastectomy was performed in 84 (29.6%), mastectomy with immediate reconstruction in 69 (24.3%), and BCS in 131 patients (46.1%). Bilateral mastectomy rates were higher in women undergoing reconstruction than in those without (66.5% vs 32.2%, respectively, P<.0001). Use of internal mammary RT was low (7.8%-11.2%) and did not differ between surgical approaches. Supraclavicular RT rate ranged from 46.6% to 52.2% and did not differ between surgical approaches but was omitted in 193 or 408 node-positive patients (47.3%). Rate of axillary RT was more frequent in patients who remained node-positive (P=.002). However, 22% of patients who converted to node-negative still received axillary RT. Post-mastectomy RT was more frequently omitted after reconstruction than mastectomy (23.9% vs 12.1%, respectively, P=.002) and was omitted in 19 of 107 patients (17.8%) with residual node-positive disease in the reconstruction group. CONCLUSIONS: Most clinically node-positive patients treated with NAC undergoing mastectomy receive RT. RT is less common in patients undergoing reconstruction. There is wide variability in RT fields. These practice patterns conflict with expert recommendations and ongoing trial guidelines. There is a significant need for greater uniformity and guidelines regarding RT following NAC.
PURPOSE: American College of Surgeons Oncology Group Z1071 was a prospective trial evaluating the false negative rate of sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy (NAC) in breast cancerpatients with initial node-positive disease. Radiation therapy (RT) decisions were made at the discretion of treating physicians, providing an opportunity to evaluate variability in practice patterns following NAC. METHODS AND MATERIALS: Of 756 patients enrolled from July 2009 to June 2011, 685 met all eligibility requirements. Surgical approach, RT, and radiation field design were analyzed based on presenting clinical and pathologic factors. RESULTS: Of 401 node-positive patients, mastectomy was performed in 148 (36.9%), mastectomy with immediate reconstruction in 107 (26.7%), and breast-conserving surgery (BCS) in 146 patients (36.4%). Of the 284 pathologically node-negative patients, mastectomy was performed in 84 (29.6%), mastectomy with immediate reconstruction in 69 (24.3%), and BCS in 131 patients (46.1%). Bilateral mastectomy rates were higher in women undergoing reconstruction than in those without (66.5% vs 32.2%, respectively, P<.0001). Use of internal mammary RT was low (7.8%-11.2%) and did not differ between surgical approaches. Supraclavicular RT rate ranged from 46.6% to 52.2% and did not differ between surgical approaches but was omitted in 193 or 408 node-positive patients (47.3%). Rate of axillary RT was more frequent in patients who remained node-positive (P=.002). However, 22% of patients who converted to node-negative still received axillary RT. Post-mastectomy RT was more frequently omitted after reconstruction than mastectomy (23.9% vs 12.1%, respectively, P=.002) and was omitted in 19 of 107 patients (17.8%) with residual node-positive disease in the reconstruction group. CONCLUSIONS: Most clinically node-positive patients treated with NAC undergoing mastectomy receive RT. RT is less common in patients undergoing reconstruction. There is wide variability in RT fields. These practice patterns conflict with expert recommendations and ongoing trial guidelines. There is a significant need for greater uniformity and guidelines regarding RT following NAC.
Authors: Thomas A Buchholz; Susan L Tucker; Lawrence Masullo; Henry M Kuerer; Jessica Erwin; Jessica Salas; Debbie Frye; Eric A Strom; Marsha D McNeese; George Perkins; Angela Katz; S Eva Singletary; Kelly K Hunt; Aman U Buzdar; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Starr Koslow; Lindsay A Pharmer; Amie M Scott; Michelle Stempel; Monica Morrow; Andrea L Pusic; Tari A King Journal: Ann Surg Oncol Date: 2013-05-30 Impact factor: 5.344
Authors: Sean E McGuire; Ana M Gonzalez-Angulo; Eugene H Huang; Susan L Tucker; Shu-Wan C Kau; Tse-Kuan Yu; Eric A Strom; Julia L Oh; Wendy A Woodward; Welela Tereffe; Kelly K Hunt; Henry M Kuerer; Aysegul A Sahin; Gabriel N Hortobagyi; Thomas A Buchholz Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-06 Impact factor: 7.038
Authors: Thomas A Buchholz; Constance D Lehman; Jay R Harris; Barbara A Pockaj; Nagi Khouri; Nola F Hylton; Michael J Miller; Timothy Whelan; Lori J Pierce; Laura J Esserman; Lisa A Newman; Barbara L Smith; Harry D Bear; Eleftherios P Mamounas Journal: J Clin Oncol Date: 2008-02-10 Impact factor: 44.544
Authors: Priya Rastogi; Stewart J Anderson; Harry D Bear; Charles E Geyer; Morton S Kahlenberg; André Robidoux; Richard G Margolese; James L Hoehn; Victor G Vogel; Shaker R Dakhil; Deimante Tamkus; Karen M King; Eduardo R Pajon; Mary Johanna Wright; Jean Robert; Soonmyung Paik; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2008-02-10 Impact factor: 44.544
Authors: Julie R Gralow; Harold J Burstein; William Wood; Gabriel N Hortobagyi; Luca Gianni; Gunter von Minckwitz; Aman U Buzdar; Ian E Smith; William F Symmans; Baljit Singh; Eric P Winer Journal: J Clin Oncol Date: 2008-02-10 Impact factor: 44.544
Authors: Bruce G Haffty; Linda M McCall; Karla V Ballman; Thomas A Buchholz; Kelly K Hunt; Judy C Boughey Journal: Int J Radiat Oncol Biol Phys Date: 2019-05-11 Impact factor: 7.038
Authors: Kennya Medeiros L de B Lima; Allan A Lima Pereira; Thiago B de Freitas; Saulo Brito Silva; Heloisa de Andrade Carvalho; Max S Mano; Gustavo Nader Marta Journal: Rep Pract Oncol Radiother Date: 2018-11-28
Authors: M G Torras; E Canals; D Jurado-Bruggeman; S Marín-Borras; M Macià; J Jové; A M Boladeras; C Muñoz-Montplet; J Molero; C Picón; M Puigdemont; L Aliste; A Torrents; F Guedea; J M Borras Journal: Transl Oncol Date: 2018-04-26 Impact factor: 4.243